RWA Wealth Partners LLC Purchases 2,392 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

RWA Wealth Partners LLC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 62.1% during the fourth quarter, Holdings Channel reports. The firm owned 6,242 shares of the medical research company’s stock after purchasing an additional 2,392 shares during the quarter. RWA Wealth Partners LLC’s holdings in Thermo Fisher Scientific were worth $3,313,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TMO. International Assets Investment Management LLC lifted its position in Thermo Fisher Scientific by 43.5% during the third quarter. International Assets Investment Management LLC now owns 1,626 shares of the medical research company’s stock valued at $810,000 after purchasing an additional 493 shares during the period. Arkadios Wealth Advisors raised its position in Thermo Fisher Scientific by 33.3% in the third quarter. Arkadios Wealth Advisors now owns 896 shares of the medical research company’s stock worth $454,000 after acquiring an additional 224 shares during the period. Wedge Capital Management L L P NC raised its position in Thermo Fisher Scientific by 8.3% in the third quarter. Wedge Capital Management L L P NC now owns 740 shares of the medical research company’s stock worth $375,000 after acquiring an additional 57 shares during the period. Summit Global Investments raised its position in Thermo Fisher Scientific by 27.8% in the third quarter. Summit Global Investments now owns 1,392 shares of the medical research company’s stock worth $704,000 after acquiring an additional 303 shares during the period. Finally, Naples Global Advisors LLC raised its position in Thermo Fisher Scientific by 37.3% in the third quarter. Naples Global Advisors LLC now owns 755 shares of the medical research company’s stock worth $382,000 after acquiring an additional 205 shares during the period. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

TMO stock opened at $548.37 on Tuesday. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. The company has a fifty day simple moving average of $571.30 and a two-hundred day simple moving average of $528.18. The firm has a market capitalization of $209.32 billion, a P/E ratio of 35.49, a price-to-earnings-growth ratio of 2.30 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating the consensus estimate of $5.64 by $0.03. The business had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. Thermo Fisher Scientific’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same quarter last year, the business earned $5.40 earnings per share. Analysts anticipate that Thermo Fisher Scientific Inc. will post 21.51 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were issued a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. The ex-dividend date was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.10%.

Analysts Set New Price Targets

Several research firms have weighed in on TMO. Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Evercore ISI increased their price target on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Barclays cut shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and increased their price objective for the stock from $475.00 to $555.00 in a research note on Wednesday, January 24th. Citigroup started coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 price objective for the company. Finally, Raymond James increased their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Five research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average price target of $604.69.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $74,039,491.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $74,039,491.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.